Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
7
×
boston blog main
boston top stories
life sciences
national blog main
national top stories
7
×
novartis
7
×
roche
7
×
san francisco blog main
7
×
san francisco top stories
cancer
indiana blog main
indiana top stories
national
pfizer
raleigh-durham blog main
raleigh-durham top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
amgen
deals
immunotherapy
investing
johnson & johnson
medicare
president trump
What
drug
bio
latest
patients
roundup
blood
cancer
company
plan
acquisitions
address
advantages
albert
alzheimer’s
american
analytics
annual
approval
approves
ash
bar
biggest
biofourmis
blueprint
borne
bourla
brings
broader
cancers
carries
ceo
certain
companies
conference
crispr
data
designed
detect
developing
devices
Language
unset
unknown
Current search:
biotech
×
novartis
×
roche
×
" national top stories "
×
" san francisco blog main "
×
@xconomy.com
3 years ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More